KAIROS PHARMA, LTD. Research and Development Expense
KAIROS PHARMA, LTD. (KAPA) reported Research and Development Expense of $619.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- KAIROS PHARMA, LTD. research and development expense for the quarter ending 2026-06-30 was $619.00K, a 24.80% increase year-over-year.
- KAIROS PHARMA, LTD. research and development expense for the quarter ending 2026-03-31 was $684.00K, a 38.74% increase year-over-year.
- KAIROS PHARMA, LTD. research and development expense for the quarter ending 2025-12-31 was $538.00K, a 212.79% increase year-over-year.
- KAIROS PHARMA, LTD. research and development expense for the quarter ending 2025-09-30 was $608.00K, a 4242.86% increase year-over-year.
- KAIROS PHARMA, LTD. research and development expense for fiscal 2025 was $2.13M, a 415.70% increase from fiscal 2024.
- KAIROS PHARMA, LTD. research and development expense for fiscal 2024 was $414.00K, a 404.88% increase from fiscal 2023.
- KAIROS PHARMA, LTD. research and development expense for fiscal 2023 was $82.00K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $619.00K 10-Q · filed 2026-08-12 | $1.30M 10-Q · filed 2026-08-12 | $1.84M derived: sum of 3 quarters · filed 2026-08-12 | $2.45M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $684.00K 10-Q · filed 2026-05-13 | $1.22M derived: sum of 2 quarters · filed 2026-05-13 | $1.83M derived: sum of 3 quarters · filed 2026-05-13 | $2.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.15M derived: sum of 2 quarters · filed 2026-03-31 | $1.64M derived: sum of 3 quarters · filed 2026-08-12 | $2.13M 10-K · filed 2026-03-31 |
| 2025-09-30 | $608.00K 10-Q · filed 2025-11-14 | $1.10M derived: sum of 2 quarters · filed 2026-08-12 | $1.60M 10-Q · filed 2025-11-14 | $1.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $496.00K 10-Q · filed 2026-08-12 | $989.00K 10-Q · filed 2026-08-12 | $1.16M derived: sum of 3 quarters · filed 2026-08-12 | $1.18M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $493.00K 10-Q · filed 2026-05-13 | $665.00K derived: sum of 2 quarters · filed 2026-05-13 | $679.00K derived: sum of 3 quarters · filed 2026-05-13 | $742.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $186.00K derived: sum of 2 quarters · filed 2026-03-31 | $249.00K derived: sum of 3 quarters · filed 2026-03-31 | $414.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $14.00K 10-Q · filed 2025-11-14 | $77.00K derived: sum of 2 quarters · filed 2025-11-14 | $242.00K 10-Q · filed 2025-11-14 | $249.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $63.00K 10-Q · filed 2025-08-12 | $228.00K 10-Q · filed 2025-08-12 | $235.00K derived: sum of 3 quarters · filed 2025-08-12 | $268.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $165.00K 10-Q · filed 2025-05-14 | $172.00K derived: sum of 2 quarters · filed 2025-05-14 | $205.00K derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $40.00K derived: sum of 2 quarters · filed 2025-04-15 | $82.00K 10-K · filed 2025-04-15 | |
| 2023-09-30 | $33.00K 10-Q · filed 2024-11-14 | $75.00K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |